Evaxion to Discontinue EVX-03 and Focus on Duke Co-developed Glioblastoma Vaccine, EVX-05
Discontinuation of EVX-03 is a Capital Reallocation Following Failure to Enter Clinical Trials
Danish company Evaxion A/S (EVAX) is terminating the development of its personalized neoantigen DNA vaccine, EVX-03, and focusing resources on the glioblastoma vaccine, EVX-05. EVX-03 was designed to deliver patient-specific neoantigens and endogenous retroviral (ERV) antigens to antigen-presenting cells (APCs), but it failed to advance to Phase 1 clinical trials. The company is also withdrawing its plans for a Phase 1/2a clinical trial for non-small cell lung cancer in 2022. This decision appears to be a portfolio choice reflecting development timelines and cost-effectiveness rather than a definitive confirmation of technical failure.
EVX-05 is a Ready-to-Use Glioblastoma Vaccine Co-developed with Duke
EVX-05 is a preclinical-stage therapeutic vaccine that targets tumor-specific ERV-derived antigens identified by Evaxion's AI-Immunology platform. It is a development-stage asset that has not yet been assigned a brand name or international nonproprietary name (INN). The initial Phase 1 clinical trial will be led by a team led by Professor Mustafa Khasraw, Duke University School of Medicine. The research collaboration between the two parties does not include upfront payments, milestone payments, royalties, or equity investments. Unlike EVX-03, which requires patient-specific manufacturing, EVX-05 uses a common antigen, making it an off-the-shelf product that can reduce production time and costs. However, its actual efficacy and safety must be verified after the first patient is treated.
Strategy to Supplement Low Mutational Burden with ERV Antigens
Glioblastoma is a type of cancer with a low mutational burden and few typical neoantigens, which limits the response to immune checkpoint inhibitors. In a 24-tumor analysis conducted by Evaxion and Duke, vaccine design was possible using ERV and neoantigens in all samples, and 21 designs included both antigen types. The key difference of EVX-05 is that it induces T-cell responses using multiple ERV antigens that are selectively expressed in tumors compared to normal tissues. However, this is based on preclinical and bioinformatics data, so the safety, immunogenicity, and manufacturing consistency of Phase 1 clinical trials are key value inflection points.
Standard Treatment and Late-Stage Competing Vaccines Create High Barriers to Entry
Currently, the standard treatment involves surgery followed by radiation and Temodar (temozolomide, a DNA alkylating agent), and Optune Gio (tumor treating fields) and Avastin (bevacizumab, a VEGF-A inhibitor) are used in some patients after recurrence. The U.S. FDA approved temozolomide in 1999, Optune for recurrent disease in 2011 and for newly diagnosed patients in 2015, and bevacizumab for recurrent glioblastoma in 2009, with full approval in 2017 after accelerated approval. Competing products include SurVaxM (SVN53-67/M57-KLH, a survivin-targeting vaccine) in Phase 2b and DCVax-L from Northwest Biotherapeutics (NWBO), which has completed Phase 3 trials and is undergoing regulatory review in the UK. The global glioblastoma treatment market is expected to grow from USD 4.0 billion in 2025 to USD 7.9 billion in 2033. If EVX-05 enters clinical trials, demonstrating improved survival rather than just manufacturing convenience will be the key to commercial competitiveness.
In the short term, the discontinuation of EVX-03 is a capital allocation measure to prevent further spending on a personalized asset with repeated delays in entering clinical trials and to maintain a cash runway until the second half of 2027. EVX-05 is in the preclinical stage, but Duke is leading the Phase 1 clinical trial, and it uses a common ERV antigen, making it an off-the-shelf product that can reduce manufacturing complexity and early clinical costs. From a research perspective, the data that vaccine design was possible in all 24 glioblastoma samples provides evidence to support the strategy of supplementing low neoantigen burden. However, in a USD 4.0 billion market, standard treatments such as temozolomide, Optune, and bevacizumab, as well as late-stage competing products such as SurVaxM in Phase 2b and DCVax-L, which has completed Phase 3 trials, mean that clinical immunogenicity alone is not enough to differentiate the product. In the medium to long term, the company's value will depend on the initiation of Phase 1 clinical trials, confirmation of safety and T-cell responses, and subsequent partnerships.